Skip to Content

Real-world data on effectiveness of durvalumab after chemoradiotherapy

Real-world data on effectiveness of durvalumab after PACIFIC-R real-world trial confirms effectiveness of durvalumab in patients with unresectable stage III non–small cell lung cancer (NSCLC), concludes Professor Nicolas Girard in this BestPractice Nordic MEDtalk.

Nocolas_gardi

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top